Probatebeta
Target

SCN1A

Sodium channel protein type 1 subunit alpha

As of the edition of 20 October 2026, SCN1A (sodium channel protein type 1 subunit alpha, UniProt P35498) has 55 drugs tested at it and 79 companies on the list, 1 on route A and 2 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P35498
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
1
Disease areas
Nervous system; Mental health; Injuries; Cancer; Bones, joints and muscles; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive
Registered trials of its drugs
2,669

Drugs at this target

StatusCount
Marketed44
Active4
Went quiet6
Withdrawn from market1
Total55
DrugStatusFurthest phaseUS protection
LidocaineMarketedPhase 4none listed
RopivacaineMarketedPhase 4none listed
TopiramateMarketedPhase 4none listed
LamotrigineMarketedPhase 4none listed
CarbamazepineMarketedPhase 4none listed
LacosamideMarketedPhase 4Ended 2026
RiluzoleMarketedPhase 4none listed
TetracaineMarketedPhase 4none listed
Eslicarbazepine acetateMarketedPhase 4Ended 2026
ZonisamideMarketedPhase 4none listed
PhenytoinMarketedPhase 4none listed
ArticaineMarketedPhase 4none listed

12 of 55 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A1
Route B2
Engaged4
Undetermined72
Total on the list79
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
Johnson & JohnsonRoute B
PainReformRoute A

The other 76 companies at SCN1A

In the product

79 companies in all; 76 are not named here, and no score is.

See the 79 companies at SCN1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at SCN1A

Other targets in nervous system

Companies holding approvals at SCN1A